Conference Agenda
Overview and details of the sessions of this conference. Please select a date or location to show only sessions at that day or location. Please select a single session for detailed view (with abstracts and downloads if available).
|
Daily Overview |
| Session | |
|
CP8: Drugs & Drug Resistance 1 - 10 min talks Location: Lecture Theatre 1 Session Chair: Christopher Hart, Griffith University Session Chair: Hannah Smith, Griffith University | |
    | |
Combating treatment refractory giardiasis with new antigiardial compounds and novel drug combination strategies 1: Institute for Biomedicine and Glycomics, Griffith University, Nathan, Brisbane, Queensland 4111, Australia; 2: School of Environment and Science, Griffith University, Nathan, Brisbane, Queensland 4111, Australia; 3: Commonwealth Scientific and Industrial Research Organization, Biomedical Manufacturing, Clayton, Victoria 3168, Australia On an annual basis >300 million people develop giardiasis, a disease that impacts child development and the long-term health of many adults. However, there is no vaccine for this disease and treatment options are failing due to multiple factors including drug resistant parasites. Moreover, current treatment strategies are monotherapies that do little to combat the development of drug resistance. To improve this position combination therapies that include new compounds with unique mechanisms of action are needed. However, little has been done to identify best practice combination therapies for giardiasis. As a mechanism to pave the way towards the development of highly effective therapies for giardiasis we have been investigating the activity of novel compounds and compound combinations against Giardia parasites in vitro. These studies have identified multiple synergistic compound combinations that may be useful in the in vivo including combinations that have Interaction (I) values >3.0 (p<0.05). While in vivo studies are now needed to determine how these combination therapies work in clinical settings, taken together with pharmacokinetic data, these results are exciting and suggest that novel antigiardial combination therapies can be developed to help combat treatment refractory giardiasis. | |